UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38999 BioCardia, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2753988 (State or another jurisdiction of incorporation or organizat ...

Financial Data and Key Metrics Changes - Revenues for Q2 2023 were approximately $43,000, a significant decrease compared to approximately $975 million for Q1 2022, primarily due to the timing of collaboration agreement revenues [21] - Net loss for Q2 2023 was approximately $3.4 million, compared to $2.5 million in Q2 2022, mainly due to fluctuations in collaboration revenues [21] - Cash and cash equivalents at the end of the quarter were approximately $4.3 million, providing a runway into November without additional capital [22] Business Line Data and Key Metrics Changes - The CardiAMP Autologous Cell Therapy for heart failure (BCDA-01) is currently paused for new patient enrollment following a recommendation from the Data Safety Monitoring Board (DSMB) [7][8] - Enrollment for the Cardiac autologous cell therapy for chronic myocardial ischemia (BCDA-02) is progressing, with expectations to complete enrollment in the rolling cohort by Q4 2023 [15] - The CardiALLO allogeneic cell therapy for ischemic heart failure (BCD03) is in Phase I/II trials, with patient enrollment expected to begin in Q3 2023 [16] Market Data and Key Metrics Changes - The company is seeing significant enrollment increases in its clinical trials, including patients from Canada [6] - The CardiAMP Cell Therapy system submission to Japan's PMDA for ischemic heart failure is progressing, with the consultation expected to take up to four months [12] Company Strategy and Development Direction - The company is focused on advancing its cell therapy platforms to address unmet needs in cardiovascular and pulmonary diseases [5] - BioCardia aims to gather more information to decide next steps for the BCDA-01 program, including the possibility of restarting the trial with a new protocol [9][10] - Business development activities are ongoing, with the goal of closing meaningful deals by the end of the year to avoid financing [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confusion regarding the DSMB's recommendation to pause enrollment, noting that there were no reported safety issues and that patients appeared to show clinical improvement [8][9] - The company remains optimistic about the safety and efficacy of its therapies, with expectations for significant near-term catalysts from its clinical programs [20] Other Important Information - The company has received patents in Japan and Europe for its delivery systems, enhancing its intellectual property portfolio [18][19] - The allogeneic cell therapy trial for acute respiratory distress syndrome (BCDA04) has been deprioritized due to reduced patient populations [17] Q&A Session Summary Question: Focus on DSMB review and trial status - The DSMB's recommendation to pause enrollment is unique, and management is analyzing the data to understand the implications while continuing to randomize patients [24][26] Question: Benchmarks for patient follow-up - Management indicated that key metrics to monitor include mortality rates, major adverse cardiac events, and functional endpoints like the six-minute walk test [30][31]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-21419 BioCardia, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2753988 (State or another jurisdiction of incorporation or organization) (I ...

BioCardia, Inc. (NASDAQ:BCDA) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Miranda Peto – Investor Relations Peter Altman – President and Chief Executive Officer Dave McClung – Chief Financial Officer Conference Call Participants Joe Pantginis – H.C. Wainwright Kumar Raja – Roth Capital Laura Suriel – Alliance Global Partners Operator Good day ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to the BioCardia 2023 First Quarter Conference Call. At ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-21419 BioCardia, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2753988 (State or another jurisdiction of incorporation or organization) ( ...

Financial Data and Key Metrics Changes - Revenues for fiscal year 2022 increased to $1.4 million from $1.0 million in fiscal year 2021, primarily due to increased revenue from collaborative partners [23] - Total operating expenses decreased by approximately $300,000 year over year, totaling $13.3 million in 2022 compared to $13.6 million in 2021 [24] - Net loss in 2022 was $11.9 million compared to a net loss of $12.6 million in 2021, with cash used in operations totaling $10.6 million in both years [25] Business Line Data and Key Metrics Changes - The CardiAMP cell therapy platform is being advanced in two cardiac clinical indications, with significant patient enrollment and positive clinical data reported [9][10] - The allogeneic mesenchymal stem cell program for ischemic heart failure (BCDA-03) is designed for patients ineligible for the autologous therapy, with clinical grade cells ready for use [17][18] - The allogeneic mesenchymal stem cell program for acute respiratory distress syndrome (BCDA-04) is expected to commence following the initiation of BCDA-03 [19] Market Data and Key Metrics Changes - The reachable US market for the CardiAMP cell therapy programs is estimated at 1.6 million patients [9] - The company anticipates significant licensing and royalty revenues from its therapies if proven effective and commercialized [23] Company Strategy and Development Direction - The company is focused on advancing two cell therapy platforms targeting unmet cardiovascular and pulmonary diseases [6] - BioCardia aims to partner its CardiAMP cell therapy platform internationally and license its Neurokinin-1 Receptor Positive mesenchymal stem cells for other clinical indications [20] - The company is also looking to monetize its Avance transseptal introducer sheath product, which has seen significant acquisition interest in the market [21] Management's Comments on Operating Environment and Future Outlook - Management highlighted the ongoing need for new therapeutic solutions in heart failure, with current treatments showing limited impact on mortality [7] - The company is optimistic about the upcoming discussions with the FDA regarding the adaptive statistical analysis plan, which could enhance the trial's design and outcomes [35][52] - Management emphasized the importance of maximizing the probability of technical success while ensuring near-term commercial viability [36] Other Important Information - The company has received breakthrough device designation from the FDA for its CardiAMP cell therapy in ischemic heart failure [36] - The next pre-specified formal data safety monitoring board review is anticipated in the second quarter of 2023 [12] Q&A Session Summary Question: Can you provide perspective on the blinded echo data for the rolling cohort? - Management explained that the patient population included those with a left ventricular ejection fraction of 20% to 40%, and the results showed a 35% improvement in ejection fraction with 100% survival at two-year follow-up [28][29] Question: What are the immediate needs regarding manufacturing capacity? - Management stated that current manufacturing capabilities are sufficient for all ongoing clinical trials, with room for expansion if needed [30][32] Question: What are the expectations for the upcoming FDA call? - Management indicated that they expect clarity on the adaptive statistical analysis plan and emphasized the importance of patient safety data in trial design [51][52] Question: What is the status of the BCDA-02 trial? - Management confirmed that the rolling cohort is up to 10 patients, and they are working to streamline the trial design for faster enrollment [53][54] Question: How does the company plan to enhance enrollment across its trials? - Management noted that patients excluded from the CardiAMP trial could qualify for the chronic myocardial ischemia trial, providing multiple opportunities for patient inclusion [55]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-21419 BIOCARDIA, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2753988 (State or other jurisdiction of incorporation or organization) (I.R.S. ...

BioCardia, Inc. (NASDAQ:BCDA) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Jules Abraham - CORE IR Peter Altman - President & CEO David McClung - CFO Conference Call Participants Joe Pantginis - H.C. Wainwright Michael Okunewitch - Maxim James Molloy - Alliance Global Partners Operator Good day, and welcome to the BioCardia 2022 Third Quarter Conference Call. [Operator Instructions]. I would now like to turn the conference over to Jules Abraham of CORE IR, the Company's ...

Financial Data and Key Metrics Changes - In Q2 2022, the company reported revenues of approximately $1 million with a net loss of $2.5 million, an improvement from a net loss of $3.5 million in Q2 2021, primarily due to increased collaboration revenues [17][18] - Research and development expenses remained flat at $2.3 million in Q2 2022 compared to $2.4 million in Q2 2021, while SG&A expenses were unchanged at $1.2 million [19] - The company ended Q2 2022 with cash totaling $8.6 million, providing a runway to the first quarter of 2023 [19] Business Line Data and Key Metrics Changes - The company is focused on advancing two cell therapy platforms targeting ischemic heart failure and chronic myocardial ischemia, with the lead heart failure program having 114 patients enrolled [8][12] - The company has also initiated an allogeneic MSC program for heart failure (BCDA-03) and a program for acute respiratory distress syndrome (BCDA-04), with the latter approved by the FDA in April [15][16] Market Data and Key Metrics Changes - The Center for Medicare and Medicaid Services (CMS) increased reimbursement for clinical sites to $20,000 per patient procedure, retroactive to April 1, 2022, enhancing confidence among clinical partners [8] - The company is expanding its clinical trial sites, including the activation of a site in Canada, which is critical for enrollment [9][21] Company Strategy and Development Direction - The company aims to complete enrollment in the CardiAMP Heart Failure Trial by 2023 and the CardiAMP Chronic Myocardial Ischemia Trial with an interim readout [12] - The company is pursuing international partnerships for its CardiAMP Cell Therapy platform and licensing its catheter-based biotherapeutic delivery system [17] Management's Comments on Operating Environment and Future Outlook - Management highlighted the significant unmet need in heart failure, affecting over 26 million people worldwide, and emphasized the importance of their breakthrough designation from the FDA [6][7] - The company is optimistic about its allogeneic MSC program and its potential to address local and systemic inflammation in patients recovering from acute respiratory distress [16][40] Other Important Information - The company is working on business development activities to secure non-dilutive financing and has raised $1.5 million by selling shares under its ATM facility [19][20] - The company is actively engaging with Japan's PMDA for the approval of its CardiAMP Cell Therapy, with a focus on enhancing comfort with their clinical data [13][28] Q&A Session Summary Question: When do you expect the first patient to be treated in Canada and when do you expect the other three sites to come onboard? - The first site in Canada is currently screening patients, and the other three sites are expected to come onboard soon [21] Question: What kind of results are you seeing in the U.S. regarding patient enrollment? - The company is working to enhance the ease of enrolling patients and has seen sites actively enrolling as staffing improves [23][24] Question: Can you discuss the next steps with PMDA in Japan? - The next steps involve resubmitting information in a new format and addressing feedback from the last consultation [48] Question: What is the strategy for commercialization in Japan if approved? - The company is exploring distribution deals and has engaged with potential partners in Japan [31] Question: How does the allogeneic program differentiate from other mesenchymal stem cell approaches? - The allogeneic program utilizes Neurokinin 1 receptor positive cells, which are believed to enhance therapeutic efficacy [35][36] Question: How easy or difficult will it be to enroll patients given the unpredictable trajectory of COVID-19? - The trial design allows for a smaller number of patients, and logistical challenges are manageable based on prior experience [44]